Suppr超能文献

干细胞在溶酶体贮积症中的应用:进展与持续挑战。

Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.

机构信息

Department of Medical Biology, Faculty of Medicine, Atilim University, Ankara, Turkey.

Department of Stem Cell Sciences, Hacettepe University Graduate School of Health Sciences, Ankara, Turkey.

出版信息

Adv Exp Med Biol. 2021;1347:135-162. doi: 10.1007/5584_2021_639.

Abstract

Lysosomal storage disorders (LSDs) are rare inborn errors of metabolism caused by defects in lysosomal function. These diseases are characterized by accumulation of completely or partially degraded substrates in the lysosomes leading to cellular dysfunction of the affected cells. Currently, enzyme replacement therapies (ERTs), treatments directed at substrate reduction (SRT), and hematopoietic stem cell (HSC) transplantation are the only treatment options for LSDs, and the effects of these treatments depend strongly on the type of LSD and the time of initiation of treatment. However, some of the LSDs still lack a durable and curative treatment. Therefore, a variety of novel treatments for LSD patients has been developed in the past few years. However, despite significant progress, the efficacy of some of these treatments remains limited because these therapies are often initiated after irreversible organ damage has occurred.Here, we provide an overview of the known effects of LSDs on stem cell function, as well as a synopsis of available stem cell-based cell and gene therapies that have been/are being developed for the treatment of LSDs. We discuss the advantages and disadvantages of use of hematopoietic stem cell (HSC), mesenchymal stem cell (MSC), and induced pluripotent stem cell (iPSC)-related (gene) therapies. An overview of current research data indicates that when stem cell and/or gene therapy applications are used in combination with existing therapies such as ERT, SRT, and chaperone therapies, promising results can be achieved, showing that these treatments may result in alleviation of existing symptoms and/or prevention of progression of the disease. All together, these studies offer some insight in LSD stem cell biology and provide a hopeful perspective for the use of stem cells. Further development and improvement of these stem cell (gene) combination therapies may greatly improve the current treatment options and outcomes of patients with a LSD.

摘要

溶酶体贮积症(LSDs)是一类由溶酶体功能缺陷引起的罕见的先天性代谢缺陷。这些疾病的特征是完全或部分降解的底物在溶酶体中积累,导致受影响细胞的细胞功能障碍。目前,酶替代疗法(ERT)、底物减少治疗(SRT)和造血干细胞(HSC)移植是 LSDs 的唯一治疗选择,这些治疗的效果强烈依赖于 LSD 的类型和治疗开始的时间。然而,一些 LSD 仍然缺乏持久和治愈的治疗方法。因此,在过去几年中,已经开发出了多种治疗 LSD 患者的新方法。然而,尽管取得了显著进展,但由于这些治疗方法通常在不可逆的器官损伤发生后才开始使用,因此其中一些治疗方法的疗效仍然有限。在这里,我们提供了 LSD 对干细胞功能的已知影响的概述,以及目前正在开发或已经开发用于治疗 LSD 的基于干细胞的细胞和基因治疗的概要。我们讨论了使用造血干细胞(HSC)、间充质干细胞(MSC)和诱导多能干细胞(iPSC)相关(基因)治疗的优缺点。目前研究数据的概述表明,当干细胞和/或基因治疗应用与现有的治疗方法(如 ERT、SRT 和伴侣蛋白治疗)结合使用时,可以取得有希望的结果,表明这些治疗方法可能会缓解现有症状和/或阻止疾病的进展。所有这些研究都为 LSD 干细胞生物学提供了一些见解,并为干细胞的应用提供了一个有希望的前景。进一步开发和改进这些干细胞(基因)联合治疗方法可能会极大地改善目前 LSD 患者的治疗选择和结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验